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Abstract 
Each year, more than 2 million women are diagnosed with breast or cervical cancer, yet 
where a woman lives, her socioeconomic status and agency largely determines whether she 
will develop one of these cancers  and will ultimately survive.  In regions with limited 
resources, fragile or fragmented health systems, cancer contributes to the cycle of poverty.   
There are proven and cost-effective interventions for both these common cancers, yet for so 
many women access to these is beyond reach. These inequities highlight the urgent need for  
sustainable investments in the entire spectrum of cancer control, from prevention to palliative 
care, and in the development of high-quality population-based cancer registries, in low- and 
middle-income countries. In this first Series paper we describe the burden of breast and 
cervical cancer with an emphasis on global and regional trends in incidence, mortality and 
survival, and the impact, particularly among socioeconomically disadvantaged women in 
different settings. 
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Introduction 
Cancer is a leading cause of premature death and disability worldwide, particularly in 
women1,2. It is a rapidly growing crisis in low- and middle-income countries (LMICs), where 
the epidemiological transition continues to shift the burden of disease from predominantly 
infectious causes to chronic, non-communicable diseases (NCDs)3. Many countries, 
particularly those with weak health systems, are struggling to cope with the rapid rise in non-
communicable diseases while still experiencing high maternal and child mortality rates, and 
high mortality rates from infectious diseases (including malaria, TB, HIV/AIDS) as well as 
malnutrition.  
 
Globally, more than 2 million women are diagnosed with breast or cervical cancer each year, 
but where a woman lives, in which country, region, or setting in relation to the nearest  health 
care services, and how she lives- poor or otherwise socially disenfranchised, largely 
determines whether she develops one of these cancers, how early she presents, and if she has 
access to affordable, good quality diagnostic and treatment services. This is particularly 
striking for cervical cancer, as approximately 85% of women diagnosed and 88% of women 
women who die from cervical cancer live in a LMIC3. There are proven approaches to reduce 
these gross inequities,  yet for most women there are few opportunities to access these life-
saving interventions. In many countries, and in many lower-resource areas within countries, 
implementation of HPV vaccination is limited4, as is the availability of, and access to early 
detection programmes, cancer surgery5, essential cancer medicines6, radiotherapy7, palliative 
care8, as well as support for those who survive, sometimes called “survivorship care”.   
 
Disability and premature death from breast or cervical cancer is a preventable tragedy for 
hundreds of thousands of women and their families each year. In 2012, breast and cervical 
cancer took the lives of 522 000 and 266 000 women respectively3; as such, close to half a 
million more women died from these two cancers alone than from complications of 
pregnancy or childbirth (303 000 maternal deaths in 2015, according to UNFPA)9. A further 
152 000 women died from ovarian cancer and 76 000 women from endometrial cancer3. But 
where do women’s cancers fit on the global health agenda? In high-income countries there is 
noteworthy advocacy, media attention and funding for research and treatment of cancer, but 
in many lower-resource settings, breast, cervical and other gynaecological cancers are 
effectively "neglected diseases"10. That these diseases cause considerable disability, 
premature death, disruption of family life and loss to the national economy, thus exacerbating 
the cycle of poverty11, has been largely ignored. 
 
Only 5% of global spending on cancer is directed toward the majority of countries where the 
greatest burden exists12. Health inequities are differences in health “…that are unnecessary, 
avoidable, unfair and unjust”13.  Poor health within countries and inequities between 
countries reflect an unequal distribution of power, income, goods, and services that result 
from “ineffective social policies, unfair economic arrangements, and bad politics”14.  Cancers 
that affect primarily women present particular challenges in terms of achieving health equity. 
Elevating the status of women will be one of the key drivers in reducing disparities in cancer 
outcomes within and between countries. 
 
The Lancet Series on women’s cancers seeks to provide an advocacy and action framework 
for radically improving progress toward closing the “global cancer divide”11 for women. The 
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three papers will focus on the global burden of breast and cervical cancer (Series paper 1), the 
untapped potential of proven and promising interventions, the challenges and opportunities to 
take these to scale while strengthening health systems (Series paper 2), and the provision of 
recommendations for translating evidence to policy, in order to reduce inequities and improve 
cancer survival for women (Series paper 3).  
 
In this first paper we describe the burden of breast and cervical cancer, with an emphasis on 
global and regional trends in incidence, mortality and survival; the social and economic 
impact on women and their families, and the disparities in cancer survival among 
socioeconomically disadvantaged women. Endometrial, ovarian, and other gynaecological 
cancers are important contributors to cancer mortality, but this Series will focus primarily on 
breast and cervical cancer, as two of the greatest contributors to cancer mortality and 
morbidity in women worldwide. As highlighted in this review, breast and cervical cancer will 
continue to pose particularly important challenges as well as opportunities to strengthen 
health systems for decades to come. Cervical cancer is largely preventable through public 
health interventions, for example, HPV vaccination for girls age 9-13, and screening with 
treatment of pre-cancerous lesions is among the few cancer-related so-called “Best Buys” or 
“very cost effective strategies” according to World Health Organization’s Global Action Plan 
for the Prevention and Control of Noncommunicable Diseases (2013-2020)15. Both HPV 
vaccination as well as screening and treatment of pre-cancerous cervical lesions are also 
included in the package of essential interventions for cancer control in LMIC, in the  Cancer 
Volume of the World Bank Group’s Disease Control Priorities, Third Edition (DCP3)16. 
Although breast cancer screening continues to generate significant debate regarding the 
magnitude of benefits and harms, opportune ages and screening intervals, cost effectiveness, 
and relevance to lower resource settings (See Series Paper 2), improving access to early 
diagnosis and treatment for breast cancer can be cost-effective, and promotion of breast 
cancer early diagnosis and treatment is listed in the DCP3 essential package16. We therefore 
address only these two cancers in this Series, as they fall under the domains of public health 
and public policy most relevant to women’s cancers.  
 
 
Aetiology of breast and cervical cancer 
 
The major known risk factors for breast cancer include female sex, age, and family history, as 
well as reproductive factors, including early age at menarche, later menopause, nulliparity, 
and first childbirth after age 30, all of which are independent risk factors17. Breastfeeding is 
independently associated with a reduced risk, with longer duration associated with a greater 
reduction in risk)18. Overweight and obesity is associated with an increased risk for post-
menopausal breast cancer, while the effect on pre-menopausal breast cancer is not as clear 
and remains an area of active study19. 
 
The most important risk factor for invasive cervical cancer is the human papilloma virus 
(HPV), of which there are several major oncogenic subtypes20 (discussed further in Series 
paper 2). Other independent risk factors include immunosuppression, particularly HIV21, and 
smoking 22. 
 
 
Breast and cervical cancer: incidence, mortality and survival  
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Each year 1.7 million women are diagnosed with breast cancer, making it the most common 
cancer in women globally3. The highest incidence rates are reported from countries in 
Northern and Western Europe (e.g. Denmark, Belgium, UK), North America, Australia and 
New Zealand (Figure 1a), but breast cancer is not confined to high-income countries, and it 
is the most commonly diagnosed cancer among women in 140 countries. With an estimated 
522 000 deaths in 2012, breast cancer is the leading cause of cancer death in women (15% of 
all cancer deaths), ahead of lung cancer (491 000 deaths). Breast cancer survival is lower in 
many LMIC and mortality rates vary more widely than incidence (Figure 1b). For example, 
breast cancer mortality rates in the Pacific Islands (Fiji), the Caribbean (The Bahamas), Sub-
Saharan Africa (Nigeria) and Southern Asia (Pakistan) are among the highest in the world3. 
 
It is estimated that 530 000 women were diagnosed with cervical cancer in 20123. It is the 
fourth most common cancer in women worldwide, but in 38 countries, including many in 
Sub-Saharan Africa, it is the most common cancer among women. The highest incidence 
rates are observed in this region (Malawi and Zimbabwe, Figure 1c), although rates are also 
high in parts of Central and South America (Guyana and Bolivia). Unlike breast cancer, the 
global map of cervical cancer mortality rates is more similar to incidence (Figure 1d). 
 
Global surveillance of cancer survival trends was recently initiated by the CONCORD-2 
study23 which analysed individual data from 279 population-based registries in 67 countries 
for over 25 million adults (15-99 years) diagnosed with one of 10 common cancers during the 
15-year period 1995-2009. Net survival up to 5 years after diagnosis was estimated after 
correction for death from other causes. Data were available from 59 countries for almost 5.5 
million women diagnosed with breast cancer. For women diagnosed during 2005–2009, 5-
year net survival was 80% or higher in 34 countries, but much lower in India (60%), 
Mongolia (57%) and South Africa (53%) (Figure 2). In the 10 years between 1995-1999 and 
2005-2009, 5-year survival from breast cancer increased in Central and South America (e.g. 
from 66% to 76% in Colombia).	Data were available from 61 countries for 602 000 women 
diagnosed with cervical cancer. The global range in 5-year net survival was very wide. For 
women diagnosed during 2005-2009, 5-year net survival was 70% or higher in 7 countries, in 
the range 60–69% in 34 countries, but below 60% in a further 20 countries. 
 
A large international study followed up cancer patients diagnosed 1990-2001 in 12 
transitioning countries and noted similarly wide variations in cancer survival24. They describe 
5-year survival for breast cancer by extent of disease: “localized” versus “regional” 
(indicating larger tumours or local spread to skin, chest wall or regional lymph nodes), for 
countries with more-developed or less-developed health services. Information on the extent 
of disease was not available for the African countries in this study. Survival for women with 
localized disease was reported to be around 90% for countries with highly developed health 
services (Singapore and Turkey), compared to 76% in countries where they were less 
developed (Thailand, India and Costa Rica), with a greater disparity for women with regional 
disease (75.4% versus 47.4% for more- and less-developed health services, respectively).  
 
While each of these studies have certain limitations, they highlight the urgent need for major 
investments in population-based cancer registration, in vital statistics including cause of 
death, and in early detection programmes, health-services infrastructure, and human 
resources23,24. 
 
Women’s cancers and human development  
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Breast and cervical cancer are indicative of the late phase of the epidemiological transition 
that characterises the rise of NCDs generally. Increasing life expectancy and declines in 
infection-related diseases (including cervical cancer) are offset by an upsurge in cancers more 
common in wealthier countries and associated with a "western" lifestyle25,26 referred to as the 
“cancer transition”25. The Human Development Index (HDI) is a composite of three basic 
dimensions of human development27: a long and healthy life measured by life expectancy at 
birth, access to knowledge based on a combination of adult literacy rate and primary to 
tertiary education enrolment rates, and a decent standard of living, based on GDP per capita 
adjusted for purchasing-power parity (PPP US$). It therefore places an emphasis on societal 
values and capabilities within a country as well as economic growth. Comparing the national 
incidence burden of the two diseases by level of (HDI), the inequity is clear: cervical cancer 
comprises up to one-third of all cancers diagnosed (in both sexes) in many low HDI settings, 
compared with less than 10% in most very high HDI countries (Figure 3). In many low (and 
some medium) HDI countries, the combined burden of breast and cervical cancer represents 
one-third of the total cancer burden in women; reductions in cervical cancer to rates observed 
in very HDI countries would effectively reduce this proportion to 10-15%.  
 
Breast cancer is the most common cancer among women in most countries, including many 
where cervical cancer is endemic. This suggests that breast cancer incidence is largely 
unrelated to national averages of the HDI. Yet the relative magnitude and the extent to which 
breast cancer incidence is rising and cervical cancer incidence falling are markers of the 
extent of social and economic transition in a given country25. Changing reproductive patterns, 
including earlier age at menarche, later first childbirth, lower parity and shorter duration of 
breast-feeding are considered to be the major causes for the uniformly rising incidence of 
breast cancer in transitioning countries26 with overweight and obesity becoming increasingly 
important factors in post-menopausal breast cancer19. In some high-income countries, 
mammographic screening has generated transient rises and subsequent falls in breast cancer 
incidence while declines in the use of hormone replacement therapy (following publication of 
the Women’s Health Initiative study in 200228) was associated with a period of declining 
breast cancer incidence, a phenomenon which seems to have stabilized since 200729. 
Meanwhile, survival has been improving and mortality has been declining in many high-
income countries, due to a combination of more effective treatments23,30,31 as well as earlier 
presentation and improved access to care.  
 
Declining cervical cancer incidence and mortality rates in many countries over the last 
decades are associated with the implementation of effective population-based screening 
programmes in high-income countries or, in transitioning countries, a diminishing prevalence 
of factors associated with persistent infection with oncogenic subtypes of the human 
papilloma virus (HPV)32. However, there are notable exceptions. For example, steady 
increases in cervical cancer incidence have been observed in the high-risk populations in 
Uganda33 and Zimbabwe34. Increasing premature cervical cancer mortality is clearly evident 
from the cohort-specific mortality trends in some countries in Eastern Europe, and Central 
Asia including former republics of the Soviet Union35.  
 
This “overlapping challenge” whereby breast cancer incidence and mortality are increasing 
while the burden of cervical cancer is not yet declining is explored with an equity lens in a 
study from Mexico, using subnational, time series data36. The report emphasizes  
the need for integrated programmes that consider both prevention and treatment 
“underpinned by a life cycle approach to effectively respond to the burden of cancer faced by 
women globally”36.   
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Singh et al37 reported on global inequities in cervical cancer incidence and mortality as a 
function of variations in HDI, socioeconomic factors, healthcare expenditures, and the 
Gender Inequality Index (GII) for 184 countries. GII is a composite score that includes 
reproductive health (maternal mortality ratio and adolescent birth rates), empowerment 
(proportion of women in parliament and those with secondary education), and economic 
status (labour force participation). Incidence and mortality were both correlated with human 
development and gender inequality. A 0.2 unit increase in GII was associated with a 24% 
increased risk of developing cervical cancer and a 42% increased risk of dying from the 
disease. While GII as a composite measure has its limitations, this study suggests that not 
only poverty reduction but increasing access to preventive health services, and elevating the 
status of women are essential to reducing cervical cancer disparities.  
 
Inequities in survival from breast and cervical cancer are not limited to the so-called “global 
south”, but also persist for women in North America and Europe (see Panel 1). Indigenous 
women, regardless of country income level, face multiple barriers to cancer care, including 
prevention, early diagnosis, and effective treatments for these cancers (see Panel 2). 
 
Predicting the future burden  
 
Figure 4 shows the predicted global burden of breast and cervical cancers in 2030. Data 
available from long-standing high-quality population-based cancer registries from medium, 
high or very high HDI countries38 suggest that if these average changes continue and were 
applicable to all countries of the world, the number of women diagnosed with breast cancer 
will increase to almost 3.2 million per year. Even if incidence rates can be maintained at 2012 
levels, a rise to 2.4 million new cases of breast cancer is predicted on the basis of 
demographic changes alone. For cervical cancer, even if the average decline would be 
observed in all countries globally, almost the same number of women will be diagnosed in 
2030 as today, around 510 000 cases. If the cervical cancer incidence rates were to remain 
unchanged, however, the number of women diagnosed annually is predicted to rise to over 
700 000 by 2030. 
 
The broader impacts on women, families and society  
Breast and cervical cancer are key contributors to the overall burden of disease in women. 
Breast cancer is the leading cause of life years spent with disability (YLD) in 119 countries 
while cervical cancer is the leading cause in 49 countries2. As a cause of premature death 
however – as estimated through years of life lost (YLL) – cervical cancer leads breast cancer 
in 23 countries, mainly in Sub-Saharan Africa and parts of Central and South America. In 
Figure 5, the DALYs (a composite measure of YLL and YLD) for cervical and breast cancer 
by four-level HDI are in opposing directions by HDI, while the relative contribution of YLL 
and YLD to DALYs also differ substantially. Breast cancer is a major contributor to the high 
overall cancer DALYs in very high HDI countries, with a relatively large contribution of 
YLD. For cervical cancer, the overall magnitude of DALYs and the large YLL component in 
low-HDI countries are striking2. 
 
A comparative analysis of epidemiologic data on breast cancer in the United States, Canada, 
India, China, Taiwan, Japan, South Korea and Sweden39 showed striking differences in the 
median age at diagnosis. The peak age at diagnosis was 40-50 years in Asian countries, and 
60-70 years for Western countries. Breast cancer has also been shown to occur earlier in life 
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in African countries where such data has been reported, with a median age of approximately 
4540-46. It remains unclear to what degree the earlier age at diagnosis is related to variations in 
the patterns of risk factors and breast cancer subtypes, or simply a reflection of the 
differences in population structures between countries of low, middle, and high income (for 
example, the median age of women in The Gambia is 20.5 years, and 41.6 in the UK47). 
 
The median age at diagnosis for invasive cervical cancer depends on the timing of exposure 
to oncogenic HPV subtypes, and on the latency between exposure, cervical dysplasia and 
other factors which can affect the likelihood of progressing to invasive disease, as described 
in the multistage model of carcinogenesis48. Once exposed to an oncogenic HPV subtype, the 
risk of developing invasive cervical cancer is greatly influenced by immune status, which in 
turn is related to age at exposure and general immunocompetence. Women who are HIV 
positive are especially at risk of progression to invasive cervical cancer21, particularly in the 
absence of screening programs. 
 
In high-resource countries, cervical cancer incidence rates increase until the age of 30-35 
years, then remain stable throughout older ages, most likely as a consequence of the delivery 
of effective screening programmes. In the United States, the median age at diagnosis of 
invasive cervical cancer is 47-48 years49, compared with 55-59 years in India50. In one multi-
centre study in Limpopo, South Africa, the mean age at diagnosis was 41.3 and 59.1 years for 
HIV-positive and HIV-negative women, respectively51. 
 
 
It is clear that breast and cervical cancer in lower-resource settings disproportionately affect 
women in the prime of life, and, as such, have significant economic and societal 
consequences.  A mother’s death has complex effects on the children and families she leaves 
behind. Women are central not only in direct care-giving for their own children, but more 
broadly in society, playing key roles in the socialization, education and health of children52,53. 
Women also make substantial, albeit under-recognized, contributions to the health-care 
labour force. Langer and colleagues have described women’s “crucial roles in the health care 
of families and communities [as] drivers of the wealth and health of nations”53. The Lancet 
Commission on Women and Health53in relation to policy for women’s cancers is explored 
further in the third paper in this Series. 
 
While a close link between maternal mortality and newborn health is established53-55, most 
studies have focussed on the early weeks and months of a child’s life, highlighting the direct 
impact of inadequate nutrition from breastfeeding. It is also important to consider the impact 
of a mother’s disability and untimely death on child survival and well-being at other key 
periods over the life course, including adolescence. Death from untreated and unpalliated 
cancer is slow, agonizing, and traumatic for patients and families. To our knowledge there are 
no published studies that specifically address the impact of a woman’s death from cancer on 
her child’s survival. Given the rising mortality, and the young ages at which many so women 
are affected, we suggest that the scope and scale of the impact of women’s cancers on the 
health and well-being of her children warrants further research. 
 
There is overwhelming evidence that investing in women’s health provides significant 
economic returns53, 56-59. As the economic cost of cancer is estimated at up to 4% of global 
GDP60, addressing the global burden of women’s cancers should be considered a sound 
investment by governments11,61,62. The case is compelling given the profound impact of these 
Lancet Series on Women’s Cancers - 
Paper 1 REV 1 April 3, 2016  
10	
	
cancers on premature death and disability, with long-lasting social, financial and economic 
consequences for the affected women, their immediate family and their wider community.  
 
Beyond evaluating the cost effectiveness of interventions for breast and cervical cancer 
control (Series Paper 2), there is a critical need for more research on the macroeconomic 
impact of women’s cancers. Of the 1,676,255 studies on breast and cervical cancer examined 
by this Series, only 3% included an economics component. Furthermore, only one in 10 of 
these were from a low or middle-income setting. The majority of the economics studies 
identified were based in high-income countries and concerned cost-effectiveness evaluations 
of interventions, often under trial conditions,. There were very few studies identified on the 
economic impact of advocacy or survivorship programmes. If we concentrate on studies 
exploring the wider economic impacts of the two cancers, the cervical cancer studies are 
quite evenly spread across all World Bank income country classifications. However, there 
were no studies on the wider economic impact of breast cancer from low-income countries.  
 
Cancer impacts the national economy and society at large through increased health 
expenditure, labour and productivity losses, and reduced investment in human and physical 
capital formation. At the micro-economic level there are profound effects on women, their 
families, individual firms and governments63,64. It is important to note that much of the work 
undertaken by women is not associated with monetary transactions and is therefore unlikely 
to be reflected in conventional macro-economic indicators53. Any calculations aiming to 
assess the economic burden associated with breast and cervical cancer should therefore 
capture non-income-generating work, such as gathering water and firewood, preparing food, 
tending to livestock, and caring for children.  
 
If we go beyond the individual impact on women and include their families, the likelihood of 
catastrophic expenditures is shockingly high in lower resource settings,66. Not infrequently,  
families faced with enormous direct and indirect costs  are forced to sell assets and accrue 
debts67-70. This already dire scenario is often exacerbated by employment-related 
complications such as decreased productivity, job loss, dismissal, and reduction of work-
related benefits71. A 2015 report of 9513 adults with cancer from eight countries in Southeast 
Asia66 found that one year after diagnosis, 29% had died, 48% experienced financial 
catastrophe, and just 23% were alive with no financial catastrophe. Low income was an 
independent predictor for financial catastrophe, as was education and stage at diagnosis.  
 
Research conducted in Argentina72, at that time a middle-income country, found a marked 
socio-economic impact on women with cervical cancer, with negative consequences on 
radiotherapy treatment compliance, despite the fact that 96% of patients reported their 
radiotherapy was free of charge, either covered by social security, the hospital or other 
agency. Study participants reported work interruption (28%), a reduction in hours worked 
(45%), loss of household income (39%) with nearly one in five families reporting a loss of 
50% or more, a reduction in the daily amount of food consumed (37%), delays in paying for 
essential services such as electricity or telephone (43%), and the sale of property or use of 
savings (38%).  
 
It is crucial to understand the social, economic, and financial impact of breast and cervical 
cancer on the health system71-75. How the health system is structured and financed16,76 dictates 
many of the socio-economic determinants and inequities of access to health services. In 
addition, the efficacy and cost-effectiveness of interventions for breast and cervical cancer 
control must be critically evaluated to help inform and prioritize evidence-based, resource-
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appropriate programs and policy-making. Understanding the political economy in which 
decisions on resource allocation are made, both nationally and internationally, is essential if 
we are to address the true impact of breast and cervical cancer77,78. These policy implications 
are examined in greater depth in paper 3 of this Series (ref). 
 
Conclusions 
 
There are huge global inequities in cancer survival for women. In lower-resource settings, 
breast and cervical cancer disproportionately affect women in the prime of life, resulting in 
significant economic and societal impact. A woman's country, region of residence, income 
level, socio-economic, ethno-cultural or migration status should no longer influence the 
likelihood of dying from these common cancers.  
 
Several global initiatives are broadening their approach to women’s health along the life-
course 79,80. The UN Secretary General’s Every Woman Every Child (EWEC) Global 
Strategy 2.0 aims to accelerate efforts to end preventable maternal, newborn, child and 
adolescent deaths by 2030. At the 2016 World Economic Forum, the new EWEC high-level 
advisory group was announced to move the new strategy forward, and to ensure that “every 
women, child, and adolescent not only survives, but thrives”81. On World Cancer Day, 2016, 
UN Secretary General Ban Ki Moon released a statement that addressed the global inequities 
in women’s cancers, and called for action to eliminate cervical cancer as a public health 
concern82.  
 
International efforts have recently led to major improvements in maternal health outcomes: a 
similar global drive is urgently needed to reduce the impact of breast and cervical cancer, 
which currently take the lives of some 800 000 women every year. Cancer control for women 
may be introduced through the new high priority health and development goals that are 
beginning to take shape. These topics are explored further in the second and third papers in 
this Series. 
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Legend to Figures 
Fig 1a. Global map of the age-standardised (world) incidence rates of female breast cancer in 
2012, with the range divided into quintiles. Source: GLOBOCAN (http://globocan.iarc.fr) 
Fig 1b. Global map of the age-standardised (world) mortality rates of female breast cancer in 
2012, with the range divided into quintiles. Source: GLOBOCAN (http://globocan.iarc.fr) 
Fig 1c. Global map of the age-standardised (world) incidence rates of cervical cancer in 2012, 
with the range divided into quintiles. Source: GLOBOCAN (http://globocan.iarc.fr) 
Fig 1d. Global map of the age-standardised (world) mortality rates of cervical cancer in 2012, 
with the range divided into quintiles. Source: GLOBOCAN (http://globocan.iarc.fr) 
Figure 2. Global distribution of age-standardised 5-year net survival (%) for women 
diagnosed aged 15-99 years with (a) breast or (b) cervical cancer during 2005–09, by 
continent and country.  
Legend: Survival estimates for each country are ranked from highest to lowest within each 
continent: Africa (grey), America (Central and South) (red); America (North) (light red); 
Asia (yellow); Europe (blue); Oceania (green). Error bars represent 95% confidence intervals. 
Survival estimates are flagged as follows: *=100% coverage of national population; †=not 
age-standardised, or §=less reliable because the only estimate(s) available are from a registry 
or registries in this category. 
Figure 3. The proportion of new cases of cervical and breast cancer in 2012 compared with 
the total cancer burden from all cancers combined in both sexes by country and four-level 
Human Development Index (HDI), and sort by HDI within these quartiles.  Source: 
GLOBOCAN (http://globocan.iarc.fr) 
Figure 4. Estimated annual percentage change (EAPC) 1993-2007 based on cancer incidence 
obtained from cancer registries included in several volumes of Cancer Incidence in Five 
Continents (top). Predicted number of breast and cervical cases (thousands) in 2030 assuming 
average trends in the EAPC are observed in every country up to 2030 seen in the incidence 
series, or assuming rates remain unchanged in every country from those estimated in 
GLOBOCAN in 2012. 
Figure 5. Age-adjusted DALYs per 100 000 population for cervical and breast cancer in 2008 
and four-level Human Development Index. DALYs=disability-adjusted life-years. 
YLL=years of life lost. YLD=years of life lived with disability. Source: Soerjomataram et al. 
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1. Globally, almost two thirds of women who die from breast cancer and nine in ten women 
who die from cervical cancer live in low- and middle-income countries. This is a largely 
preventable tragedy for hundreds of thousands of women and their families each year. 
2. Most women who develop breast or cervical cancer in a high-income country will survive; 
the opposite is true for women in most low and many middle-income countries. Where a 
woman lives, her socio-economic, ethno-cultural or migration status should no longer mean 
the difference between life and death from these common cancers, for which cost-effective, 
life-saving interventions exist.  
3. The incidence of breast cancer is expected to increase rapidly with human development. 
While invasive cervical cancer should be predicted to fall in emerging economies, this is not 
yet the case in many countries where patterns of sexual behavior are increasing the 
transmission of oncogenic HPV subtypes, and population-based organized HPV vaccination 
and cervical screening programs are not yet widely implemented.  
4. It is crucial to understand the social, economic, and financial impact of breast and cervical 
cancers, which take a disproportionate toll on women in LMIC, and in the prime of life. The 
efficacy and cost-effectiveness of interventions for breast and cervical cancer control must be 
critically evaluated to help inform and prioritise evidence-based, resource-appropriate 
programs and policy-making. 
5. Global efforts, particularly in recent years, have led to significant improvements in 
maternal health outcomes. Similar efforts are urgently needed to address breast and cervical 
cancer, which take the lives of three times as many women each year.  
 
Search Strategy and Selection Criteria 
Studies were retrieved through systematic searches on the following medical and social 
sciences electronic databases: EMBASE, Global Health, MEDLINE (OVID), Scopus, Web of 
Science and Econlit. Variations of  search terms related to ‘breast cancer’, ‘cervical cancer’, 
‘low income’, ‘middle income’, ‘developing’ countries , the individually named countries of 
relevance, ‘economic burden’ and ‘economic consequence’, were combined. We searched 
Google Scholar, scanned the reference lists of the studies retrieved and hand searched the 
resources and publications of institutional websites. Searches were limited to studies 
published in English after 1990 containing original quantitative estimates of economic 
impact. 
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PANEL 1: Cancer survival disparities in North America and Europe  
 
Disparities in breast and cervical cancer survival exist within and between high-income 
countries25, 83-85. Age-adjusted 5-year survival from breast cancer varies by as much as 20% 
between European Union countries, with lower survival recorded in Eastern European 
countries85. The international differences in survival have been attributed to differences in 
stage at diagnosis, access to optimal treatment and national levels of organisation and 
investment in health care. A European survey on the availability, reimbursement, and other 
barriers to access reveals important disparities across Europe in access to cancer medicines86. 
Even in the EU, drug shortages limit access to older, inexpensive medicines that are essential 
for treatment (with curative or palliative intent), such as tamoxifen for breast cancer, or 
cisplatin and 5-fluorouracil for cervical cancer. In view of their proven efficacy and low cost, 
these agents, which are included in the recently updated Essential Medicines List6 of the 
World Health Organization, should be made universally available for all who require them. 
 
It is unclear to what extent differences in tumour biology versus social, economic and other 
factors play a role in survival disparities within countries. A number of studies have found a 
greater proportion of triple-negative breast cancers among African-American women87,88, a 
subtype associated with a poorer survival. However, a recent population-based study in the 
US87 found persistent differences in 7-year breast cancer-specific survival between African-
American and White women, even for stage I disease. The difference in breast cancer-
specific survival remained important even after excluding triple negative tumours. This study 
did not explore access and utilization of cancer services. 
 
African-American women87-95 and women from other minority populations in the US87-91,94-
96, the UK97 and Canada98-100 tend to have lower participation in breast and cervical cancer 
screening programmes and, with some exceptions101, lower cancer survival than the 
corresponding national averages. Reasons for these disparities are poorly understood and 
include socioeconomic factors such as economic deprivation, geographic distance to cancer 
services, lack of health insurance and other social and cultural factors which could affect 
health-care seeking behaviour87-89,92,100.  
 
In recognition of the magnitude and pervasiveness of these inequities, a number of regional, 
national and international cancer organizations have established programmes and policies to 
reduce cancer disparities, not only for breast and cervical cancers but also for cancers more 
generally, in men, women and children.  
 
 
Panel 2: Cancer incidence and survival among indigenous women  
 
Indigenous people in many high-income countries have disproportionally worse health and 
lower life expectancy than their non-indigenous counterparts. A study led by IARC 
comparing the scale and profile of cancer incidence among indigenous and non-indigenous 
populations in USA, Canada, Australia and New Zealand has revealed high rates of cervical 
cancer in almost all jurisdictions, emphasising the need for targeted prevention strategies in 
these populations102.  
 
Survival from breast and cervical cancer is lower among indigenous women than the national 
averages in the US, Canada, and Australia 103-107. Vasilevska and colleagues conducted a 
systematic review and meta-analysis of cervical cancer in indigenous women in Australia, 
Lancet Series on Women’s Cancers - 
Paper 1 REV 1 April 3, 2016  
21	
	
New Zealand, Canada, and the U.S.103. Of note, they found no difference in the risk for 
cervical dysplasia or carcinoma in situ but they did find an elevated risk of invasive cervical 
cancer (pooled RR 1.72) and cervical cancer mortality (pooled RR 3.45). As the indigenous 
women had a higher risk of cervical cancer morbidity and mortality but no increased risk of 
early-stage disease, they suggest, “structural, social, or individual barriers to screening, rather 
than baseline risk factors, are influencing poor health outcomes”. 
 
There remains, however, little information on cancer incidence, survival, and the level of 
access to cancer services among indigenous populations in LMIC. Recent global and regional 
reports reviewing cancer among indigenous communities have highlighted the need for more 
attention to this issue102,108. Efforts to develop joint actions as a partnership between 
Governments, health professionals and the indigenous communities will be critical in 
reducing the elevated and avoidable burden of cancer among Indigenous peoples 
worldwide102. 
 
 
 
